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Background: Metabolic syndrome (MetS) is an aberration associated with increased risk for cancer and
inflammation. Adiponectin, an adipocyte-produced abundant protein hormone, has countering effect on the
diabetogenic and atherogenic components of MetS. Plasma levels of adiponectin are negatively correlated with
onset of cancer and cancer patient mortality. We previously performed microsatellite linkage analyses using
adiponectin as a surrogate marker and revealed two QTLs on chr5 (5p14) and chr14 (14q13).
Methods: Using individuals from 85 extended families that contributed to the linkage and who were measured for
42 clinical and biologic MetS phenotypes, we tested QTL-based SNP associations, peripheral white blood cell
(PWBC) gene expression, and the effects of cis-acting SNPs on gene expression to discover genomic elements that
could affect the pathophysiology and complications of MetS.
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Results: Adiponectin levels were found to be highly intercorrelated phenotypically with the majority of MetS traits.
QTL-specific haplotype-tagging SNPs associated with MetS phenotypes were annotated to 14 genes whose function
could influence MetS biology as well as oncogenesis or inflammation. These were mechanistically categorized into
four groups: cell-cell adhesion and mobility, signal transduction, transcription and protein sorting. Four genes were
highly prioritized: cadherin 18 (CDH18), myosin X (MYO10), anchor protein 6 of AMPK (AKAP6), and neuronal PAS
domain protein 3 (NPAS3). PWBC expression was detectable only for the following genes with multi-organ or with
multi-function properties: NPAS3, MARCH6, MYO10 and FBXL7. Strong evidence of cis-effects on the expression of
MYO10 in PWBC was found with SNPs clustered near the gene’s transcription start site. MYO10 expression in PWBC
was marginally correlated with body composition (p= 0.065) and adipokine levels in the periphery (p = 0.064).
Variants of genes AKAP6, NPAS3, MARCH6 and FBXL7 have been previously reported to be associated with insulin
resistance, inflammatory markers or adiposity studies using genome-wide approaches whereas associations of CDH18
and MYO10 with MetS traits have not been reported before.
Conclusions: Adiponectin QTLs-based SNP association and mRNA expression identified genes that could mediate
the association between MetS and cancer or inflammation.
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MetS is a cluster of phenotypes characterized by pref-
erential deposition of fat in the abdominal/visceral re-
gion, insulin resistance, dyslipidemia, increased blood
pressure and increased plasma levels of adipokines/
cytokines [1]. Its complications include increased blood
pressure/hypertension, glucose intolerance and type 2 dia-
betes. MetS has been associated with several forms of
cancer including breast, endometrial, cervical, ovarian,
esophageal, colon, rectal, pancreatic, hepatic, biliary
and kidney cancers [2]. Overweight/obesity by itself ac-
counts for 14% of cancer deaths in men and 20% in women
[2]. Childhood cancer survivors are also known to present
features of the MetS in later life [3].
Adiponectin is an adipocyte-produced kinin encoded
by the gene apM1 (adipose most abundant transcript
1) at chr3q27 [4]. Adiponectin circulates in two forms, the
low molecular weight (LMW) dimers, and the high mo-
lecular weight (HMW) oligomers. Tissue specificity of
adiponectin n-mers is determined by their relative affinity
for receptors (AdipoR1 and R2). AdipoR1 has a higher af-
finity for HMW. It is ubiquitously expressed but highly
enriched in skeletal muscle. AdipoR2 can bind both forms
and is mainly expressed in the liver [5]. Adiponectin has
been shown to enhance insulin sensitivity and to exert
anti-diabetogenic and anti-atherogenic functions as well as
anti-inflammatory and anti-angiogenic activities [6-8]. Its
plasma levels are inversely correlated with increased risk
for obesity-related malignancies [9].
To explore possible genetic mechanisms linking MetS
pathways with severe adverse outcomes such as develop-
ment of cancer, we previously conducted a genome-wide
linkage study using microsatellite markers at approxi-
mately 10 centiMorgan (cM) intervals in 1,100 individ-
uals from 170 nuclear families (out of 85 extendedfamilies) of predominantly Northern European ancestry.
This study identified two highly significant quantitative
trait loci (QTLs) on chr5p14 and chr14q13 [10]. In the
present study, we tested for genes harbored within these
QTLs that could account for the association between
MetS and carcinogenesis or systemic inflammation. For
this purpose, we evaluated 1,137 individuals from the 85
extended families that contributed to the original linkage
signals and who were phenotyped for 42 clinical and/or
biological MetS traits (described in Results). We then
performed QTL-focused SNP association and PWBC
target gene expression analyses to identify those genes
predisposing for this association.
Methods
Subjects and phenotypes
The present study cohort included 1,137 individuals
from 85 extended families. Details of their recruitment
and ascertainment traits procedures have been previ-
ously described [11,12]. Recruitment was initiated via an
obese proband (BMI ≥ 30) with minimal availability of
one obese and one never-obese (BMI ≤ 27) siblings and
at least one, preferably both, parents. The clinical pheno-
typic components, which included weight, height, BMI,
waist circumference (WC), hip circumference (HC),
waist to hip ratio (WHR), fasting glucose (FG), fasting
insulin (FI), insulin to glucose ratio (IGR), homeostasis
model assessment (HOMA), plasma triglycerides (TG),
total cholesterol (TC), LDL-cholesterol (LDL-c) and cal-
culated LDL-cholesterol levels (cal. LDL-c), HDL-
cholesterol (HDL-c), systolic and diastolic blood pressure
(sBP and dBP) and pulse, as described [11]. The biological
traits included total fat mass both in kilogram and percent-
age (Fatkg and Fatpct) and total fat free mass both in kilo-
grams and as percentage of total body mass (Leankg and
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[13]; total abdominal, visceral and subcutaneous fat size
(TAF, VF and SubQF) by computed tomography (CT)
scans of the fourth lumbar spine [14]; respiratory quotient
(RQ) and resting energy expenditure (REE) measured in
resting subjects using a Deltatrac Indirect Calorimeter
(Sensor Medics, VIASYS Healthcare, Conshohocken, PA)
after a 10 hr fast; insulin/glucose responsiveness indices:
insulin sensitivity (SI), glucose effectiveness (SG), acute in-
sulin response to glucose (AIRG) and disposition index
(DI) by Minimal Model [15]; lipids/lipoprotein sizing
[HDL median diameter (HMED), LDL-cholesterol median
diameter (LMEDn), LDL-cholesterol dominant peak diam-
eter (LDLppd) and apoB-containing non-HDL median
diameter (BMED) which includes VLDL, ILDL, LPα and
LDL] measured by polyacrylamide gradient gel electro-
phoresis [16]; circulating levels of adiponectin, leptin by a
double antibody, equilibrium RIA (Millipore Corporation,
Billerica, MA); and TNF-alpha, interleukin-1beta (IL-1β)
and interleukin-6 (IL-6)] measured as described [17]. All
study procedures for adults and children were approved by
the Institutional Review Boards of the Medical College of
Wisconsin and Children’s Hospital of Wisconsin, respect-
ively. Informed consent was obtained from the participat-
ing subjects or guardians of participating minors.
SNP genotyping and data cleaning
Genomic DNA was extracted and prepared from whole
blood using commercial kits (Puregene, Minneapolis, MN).
Genome-wide SNP genotyping was performed using
Affymetrix Genome-Wide Human SNP 6.0 arrays and
SNP calls were generated by Genotype Console 3.2. Indi-
viduals with fewer than 95% of all available markers called
were excluded. 869,222 autosomal SNPs were prepared by
Preswalk and checked for Mendelian consistency with
SimWalk2. A SNP was eliminated if: 1) fewer than 95% of
the cohort were typed successfully; 2) the SNP was
monoallelic; 3) the SNP had more than two alleles; 4) fewer
than five copies of the SNP existed in the current study co-
hort. Hardy-Weinberg equilibrium (HWE) was tested for
each SNP using SOLAR [18]; SNPs with excessive devi-
ation from HWE (p < 10-8) were excluded. Missing SNP
data were imputed with MERLIN [19].
Transcriptional profiling
Genome-wide transcriptional profiles of a subset of the
SNP genotyping cohort (369 individuals from 55 nuclear
families) were obtained as previously described [20] with
modifications. Briefly, for each individual 2.5 ml blood was
collected into a PAXgene® Blood RNA Tube (BD, Franklin
Lakes, NJ) following an overnight fast. Total RNA was iso-
lated from each tube using the PAXgene Blood RNA Kit
(Qiagen, Valencia, CA) and anti-sense RNA (aRNA) was
synthesized using the MessageAmp II-Biotin aRNA kit(Ambion, Austin, TX). A total of 1.5 μg aRNA was hy-
bridized to Illumina HumanWG-6 version 2 or version 3
chips (Illumina, San Diego, CA) and expression detected
on the IlluminaW BeadArray™ 500GX Reader. Illumina
GenomeStudio software (version 2010.3) was used for
preliminary data analysis with standard background
normalization. The data discussed in this publication have
been deposited in NCBI’s Gene Expression Omnibus [21]





In SOLAR, each SNP genotype was converted to a co-
variate measure equal to 0, 1 or 2 copies of the minor al-
lele (or, for missing genotypes, a weighted covariate
based on imputation). These covariates were included in
variance-components mixed models for measured geno-
type analyses [22] versus null models that incorporated
the random effect of kinship and fixed effects such as
age, age2, sex and their interactions. Individual scores
from a principal components analysis of representative
SNPs were also included to correct for possible popula-
tion stratification [23].
Within chromosomal regions showing the strongest
prior evidence of linkage (as logarithm of odds, LOD,
score) with MetS traits in our MRC-OB cohort, we se-
lected all available SNPs on the Affymetrics 6.0 array
that mapped within a 1-LOD confidence interval of the
maximum LOD score in each region. Each SNP covari-
ate was tested independently in a 1 degree of freedom
likelihood ratio test. To take into account the linkage
disequilibrium between SNPs in each region, we calcu-
lated the effective number of independent SNPs (Neff )
using the method of Moskvina & Schmidt [24]. Critical
p-values were calculated using Bonferroni/Šidák correc-
tion for each linkage region based on its Neff.
Gene expression analysis
Microarray data were available in two batches, one based
on Version 2 arrays (48,701 probes, 307 samples) and the
other on Version 3 (48,803 probes, 230 samples). To
guard against possible batch effects and probe differ-
ences, each batch was analyzed separately: The number
of probe transcripts detectable at p≤0.05 by BeadStudio
software was counted, a false discovery rate (FDR) was
computed across all probes, and transcripts detectable at
5% FDR were retained. Expression levels were log2
transformed and inverse-quartile normalized. Transformed
and normalized expression levels for probes that mapped
to the 1-LOD QTL regions were tested for association with
phenotypes of interest in models that included the random
effect of kinship. Gene-centric p-values were calculated by
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batches and multiple probes using Stouffer’s weighted
Z-score method [25] implemented in R.
Results
Intercorrelation between plasma adiponectin levels and
MetS phenotypes
Based on their attributes in different biological pathways,
we categorized our 42 measured MetS phenotypes into
five groups: body composition, insulin responsiveness,
lipids/lipoprotein profiles, cardiovascular performance,
and adipokine and cytokines (Table 1). Means ± SD of
the 42 MetS phenotypes and levels of their heritability
have been previously described [26]. We found that
plasma adioponectin levels were highly heritable (addi-
tive heritability, h2 = 0.48) in our study cohort. Intercor-
relation analysis of leading MetS component phenotypes
revealed significant phenotypic correlations to varied de-
grees (See the Additional file 1: Table S1). Plasma
adiponectin is also significantly correlated with the ma-
jority of tested phenotypes (29 out of 41, nominal
p<0.05). In particular, it is highly correlated with the
MetS-defining [27,28] phenotypes WC (correlation
p-value=1.86×10-22), FG (7.8×10-4), plasma TG (1.3×10-8),
plasma HDL-c (5.2×10-12), sBP (1.55×10-6) and dBP
(7.1×10-3). Overall, levels of adiponectin inversely correlate
with a phenotypes representing adverse adipose distribu-
tion (weight, BMI, WC, HC, WHR, Fatkg, Fatpct and
SubQF, VF and TAF), elevated fasting glucose levels and
insulin resistance indices (FG, FI, IGR and HOMA),
dyslipidemia (TG), cardiovascular malfunction (sBP, dBP
and pulse) and leptin. On the contrary, adiponectin levels
correlate positively with several phenotypes indexing lean-
ness (Leanpct), insulin sensitivity (SI and SG) and HDL-c.
These results indicate that adiponectin is a reliable and sig-
nificant phenotypic surrogate of both the clinical and bio-
logical traits of MetS in our cohort.
SNP genotype/phenotype association
Consistent with common practice, we defined confidence
regions for the previously defined adiponectin linkage
peaks as the physical positions adjacent to the peak
showing linkage evidence of at least LOD score - 1: 5p14
[peak LOD=4.1; chr5: 9,792,000-23,021,100bp (NCBI36/
hg18)] and 14q13 [peak LOD=3.2; chr14: 23,131,000-
36,761,868bp (NCBI36/hg18)]. Haplotype-tagging SNPs
located within these regions were tested for statistical as-
sociation with each of the 42 MetS phenotypes. To ac-
count for multiple testing within QTLs while accounting
for linkage disequilibrium (LD) among SNPs, QTL-
specific significance thresholds were calculated based
upon Bonferroni/Šidák correction for the effective num-
ber of independent SNPs at 5p14 (nSNPs =3540, neffective=
2429.61, pα=0.05= 2.11×10
-5) and 14q13 (nSNPs=3794,neffective =2760.37, pα=0.05=1.86×10
-5). SNPs that passed
region-specific significance thresholds for respective
traits and/or the highest nominally significant SNP of
each trait for each trait are shown in Tables 2 and 3.
QTL5p14
Fine-mapping of this region identified QTL-wide signifi-
cant SNP associations with body composition phenotypes,
including weight and BMI (Figure 1A and 1B). As shown
in Table 2, 7 SNPs led by rs10061119 are mapped to an in-
tronic region of the gene encoding cadherin 18 (CDH18).
In addition, SNPs annotated near myosin X (MYO10),
showed nominally significant associations with plasma
adiponectin (Table 2 and Figure 1C). The second strongest
SNP association cluster with adiponectin (Figure 1C,
pointed by a red arrow) is intergenic and is approximately
400kb 5’ to the transcription start site of the cadherin-18
gene CDH18 (Figure 1C, framed in green).
SNPs mapped to CDH18 (cadherin 18) were also
nominally associated with other MetS phenotypes in-
cluding WC, HC and RQ. SNP rs404639 mapped to
an intron of CDH12, another member of the cadherin
family, and was associated with plasma leptin. SNP
rs6894869 was significantly associated with lipid par-
ticle size phenotype BMED and mapped to an intron
of CTNND2, which functions in the same pathway as
cadherins, plays a crucial role in CNS development [29]
and is a partner of the Alzheimer disease-associated
gene presenilin-1 [30]. MYO10 was also nominally
associated with Leankg, LDLppd and IL-6. For the
other MetS traits the strongest associations were
with SNPs near several other genes with biological
relevance to cancer. SNPs near TAG, a tumor antigen
gene, were associated with HMED (high density lipid
particle sizing), REE (resting energy expenditure), and
insulin phenotypes FG and HOMA. SNPs mapped to
MARCH11 and FBXL7, two ubiquitin ligases involved
in the pro-inflammation pathways, were associated
with total fat mass, FI, SI and pro-inflammation
marker IL-1beta (MARCH11), and with lean body
mass (FBXL7).
QTL14q13
This QTL region has a high density of genes with regula-
tory functions including signal transduction, transcription
and post-transcription processing. Our fine-mapping iden-
tified SNPs associated with each of the 42 MetS pheno-
types. Table 3 summarizes the SNPs most highly associated
with each trait, the attributes of the variants, and the gene
ontology of their annotated genes. Variants of NPAS3, a
neuronal transcription factor thought to be involved in
brain tumor suppression, were found to be associated with
11 of the MetS phenotypes (Fatkg, Leankg, SubQF, TAF,
REE, TG, TC, LDL-c, pulse, IL1b and IL-6), suggesting a
Table 1 Correlations of plasma adiponectin with the other MetS phenotypes in our cohort
Phenotype Correlation p-value Inter-correlation (ρ)
Body composition Weight, kg 7.37×10-17 −0.29
Height, cm 0.030 −0.08
BMI, kg/m2 4.22×10
-16 −0.29
Waist circumference (WC), cm 1.90×10-22 −0.34
Hip circumference (HC), cm 4.80×10-16 −0.29
Waist to Hip ratio (WHR) 0.000025 −0.15
Total Fat Mass (Fatkg), kg 0.00078 −0.17
Total Fat Mass (Fatpct),% 0.032 −0.11
Total Lean Mass (Leankg), kg 0.00013 −0.20
Total Lean Mass (Leanpct), % 0.026 0.11
Subcutaneous Fat (SubQF), g 0.0012 −0.18
Visceral Fat (VF), g 2.04×10-8 −0.30
Total Abdominal Fat (TAF), g 0.000039 −0.23
Respiratory Quotient (RQ) 0.78 0.02
Resting Energy Expenditure (REE), kcal/24 hrs 8.15×10-7 −0.26
REE/weight, kcal/24hrs/kg 0.29 0.06
REE/Lean mass (REE/LM), kcal/24hrs/kg 0.16 −0.08
Insulin responsiveness Fasting Glucose (FG), mmol/l 0.00078 −0.12
Fasting Insulin (FI),pmol/l 8.85×10-8 −0.18
Insulin/glucose (IGR) 6.63×10-6 −0.15
Homeostasis model assessment (HOMA) 3.40×10-8 −0.19
Insulin Sensitivity (SI), (× 10-4/min/μU/ml) 1.28×10-6 0.26
Glucose Effectiveness (SG), min-1 0.068 0.10
Acute Insulin Response to glucose (AIRG), μU/ml × 10min 0.45 −0.04
Disposition Index (DI), AUC (Insulin0-10 min) × SI 0.012 0.14
Lipids/lipoprotein profiles Triglycerides (TG), mmol/l 1.30×10-8 −0.20
Total Cholesterol (TC), mmol/l 0.50 −0.02
LDL-cholesterol (LDL-c), mmol/l 0.42 −0.03
Calculated LDL-C (cal. LDL-c), mmol/l 0.92 0.00
HDL-cholesterol (HDL-c), mmol/l 5.17×10-12 0.25
HMED, nm 0.000020 0.18
LMEDn, nm 0.000851 0.14
LDLppd, nm 4.43×10-6 0.19
BMED, nm 0.058 0.08
Cardiovascular performance Systolic Blood Pressure (sBP), mmHg 1.55×10-6 −0.16
Diastolic Blood Pressure (dBP), mmHg 0.0071 −0.09
Pulse, beats/min 0.023 −0.08
Adipokine and cytokines Leptin, ng/ml 5.64×10-11 −0.23
TNF-alpha, pg/ml 0.24 0.04
Interleukin-1 beta (IL-1β), pg/ml 0.89 0.01
Interleukin-6 (IL-6), pg/ml 0.81 −0.01
The pair-wise intercorrelation (ρ) and its respective significance (p-value) between plasma adiponectin levels and each of the other MetS phenotypes are shown.
Inter-correlations that passed the nominal significance cutoff (p<0.05) are depicted in bold italic.
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Table 2 MetS SNP association with phenotypes and their gene annotation at 5p14 QTL
Variant Minor allele MAF -LOG(p) Associated phenotypes Nearest gene Location Annotation
rs10061119 T 0.26 5.07 Weight CDH18 intron Cell Cell adhesion
rs13357704 A 0.26 5.07 Weight CDH18 intron Cell Cell adhesion
rs10805723 G 0.25 5.03 Weight CDH18 intron Cell Cell adhesion
rs16887308 T 0.26 5.03 Weight CDH18 intron Cell Cell adhesion
rs4386736 A 0.26 5.03 Weight CDH18 intron Cell Cell adhesion
rs6879762 C 0.26 5.03 Weight CDH18 intron Cell Cell adhesion
rs10062513 G 0.25 4.68 Weight CDH18 intron Cell Cell adhesion
rs13355121 C 0.25 4.68 Weight CDH18 intron Cell Cell adhesion
rs10062864 A 0.25 4.57 Weight CDH18 intron Cell Cell adhesion
rs163282 A 0.26 4.27 Height FAM134B intron Neuron maintenance
rs10061119 T 0.26 4.82 BMI CDH18 intron Cell Cell adhesion
rs13357704 A 0.26 4.82 BMI CDH18 intron Cell Cell adhesion
rs10805723 G 0.25 4.77 BMI CDH18 intron Cell Cell adhesion
rs16887308 T 0.26 4.77 BMI CDH18 intron Cell Cell adhesion
rs4386736 A 0.26 4.77 BMI CDH18 intron Cell Cell adhesion
rs6879762 C 0.26 4.77 BMI CDH18 intron Cell Cell adhesion
rs13355121 C 0.25 4.52 BMI CDH18 intron Cell Cell adhesion
rs10062864 A 0.25 4.43 BMI CDH18 intron Cell Cell adhesion
rs10061119 T 0.26 4.66 WC CDH18 intron Cell Cell adhesion
rs13357704 A 0.26 4.66 WC CDH18 intron Cell Cell adhesion
rs10805723 G 0.25 4.57 WC CDH18 intron Cell Cell adhesion
rs16887308 T 0.26 4.57 WC CDH18 intron Cell Cell adhesion
rs4386736 A 0.26 4.57 WC CDH18 intron Cell Cell adhesion
rs6879762 C 0.26 4.57 WC CDH18 intron Cell Cell adhesion
rs995021 C 0.49 3.57 HC CDH18 intron Cell Cell adhesion
rs1864220 G 0.07 3.45 WHR FBXL7 intron Protein sorting
rs860545 T 0.16 2.89 Fatkg MARCH11 intergenic Protein sorting
rs10223312 T 0.01 3.52 Fatpct mRNA BC033144 intergenic unknown function
rs17707882 A 0.04 4.47 Leankg MYO10 intron Cell Cell adhesion
rs10223312 T 0.01 3.54 Leanpct mRNA BC033144 intergenic unknown function
rs1840870 C 0.44 2.44 SubQF EST BG220738 intergenic unknown function
rs11134371 T 0.33 4.04 VF LOC285692 intron unknown function
rs17275322 G 0.03 2.82 TAF LOC285692 intron unknown function
rs12652510 C 0.19 3.11 RQ CDH18 intron Cell Cell adhesion
rs10065719 G 0.14 2.74 REE AY330599 intergenic tumor antigen
rs6859862 C 0.41 3.61 REE/weight DNAH5 intron motor protein
rs1809880 G 0.06 3.16 REE/Lean ROPN1L intron sperm protein
rs7721328 G 0.17 3.57 FG mRNA TAG1 intron tumor antigen
rs2582660 C 0.18 2.88 FI MARCH11 intergenic Protein sorting
rs16902967 A 0.03 3.77 IGR DNAH5 intergenic motor protein
rs4327597 A 0.14 3.25 HOMA TAG intron tumor antigen
rs831657 G 0.14 3.23 SI MARCH11 intergenic protein sorting
rs1551936 T 0.15 3.44 SG FAM134B intron Neuron maintenance
rs2929724 C 0.50 3.30 AIR LOC285696 intron unknown function
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Table 2 MetS SNP association with phenotypes and their gene annotation at 5p14 QTL (Continued)
rs10805650 G 0.33 3.11 DI EST BM682321 intergenic unknown function
rs16887451 C 0.07 3.10 TG mRNA BC028204 intron unknown function
rs17839277 T 0.03 3.55 TC mRNA BC028204 intergenic unknown function
rs12659663 A 0.25 4.17 LDL-c mRNA BC028204 intron unknown function
rs12659663 A 0.25 3.87 cal. LDL-c mRNA BC028204 intron unknown function
rs6883134 G 0.06 3.25 HDL-c TRIO mRNA intron protein interaction
rs10065719 G 0.14 4.48 HMED AY330599 intergenic tumor antigen
rs10079252 G 0.49 4.30 LMEDn mRNA U92022 intergenic transposon Hsmar2
rs10073730 C 0.01 3.77 LDLppd MYO10 intron Cell Cell adhesion
rs6894869 C 0.01 5.13 BMED CTNND2 intron Cell Cell adhesion
rs5745297 A 0.07 3.58 sBP DAP 3’ UTR cell death
rs6450583 G 0.21 3.27 dBP mRNA BC028204 intergenic unknown function
rs1971391 A 0.44 3.10 Pulse mRNA AK130861 intergenic unknown function
rs31509 G 0.28 3.33 Adiponectin MYO10 intron Cell Cell adhesion
rs404639 G 0.06 4.29 Leptin CDH12 intron Cell Cell adhesion
rs6893920 G 0.22 4.04 TNF-alpha mRNA U92022 intergenic transposon Hsmar2
rs7730897 T 0.10 3.47 IL-1β MARCH11 intergenic protein sorting
rs17707882 A 0.04 3.77 IL-6 MYO10 intron Cell Cell adhesion
SNPs within 1 LOD reduction from the linkage peak were tested for associations against the 42 phenotypes. Annotated genes and their known function were
derived from the NCBI build 36 human genome assembly. Annotations were determined at the position and within 250kb up- and downstream of the associated
SNP. Data shown in column “-Log10(p)” are levels of the highest association. SNP associations that exceed statistical QTL-specific significance threshold
are bolded.
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(TG and TC) were borderline significant, marginally
reaching the regional threshold (Table 3 and Figure 2A).
SNPs near BRMS1L, a breast cancer suppressor gene,
was associated with LMEDn and LDLppd. SNPs of
EGLN3, a regulator of transcription factor HIF that af-
fects apoptosis in hemangioblastoma and clear cell
renal cancer, were associated with IGR and LDL-c.
SNPs of NOVA1, a post-transcription processing of the
GnRH paraneoplastic antigen, were associated at nom-
inal significance with several phenotypes including
weight, BMI, WC, FG, FI, HOMA, SI, AIR, and sBP.
Prominent SNP associations in this region were
mapped to genes for signal transducers include ki-
nases and kinase-related proteins AKAP6 and PRKD1
and the phosphotase PPP2R3C. SNPs of the gene en-
coding AKAP6, an anchor protein for AMPK, which
may connect MetS with cancer, were associated with
HC, RQ and REE/leanmass. SNPs of PRKD1, a kinase
that phosphorylates and therefore activates E-cadherin
functions, were associated with WHR, Fatpct, Leanpct,
and TNF-alpha. SNPs of PPP2R3C, a protein phos-
phatase, were associated with DI. SNP rs9322942 of
SRP54, the gene for a signal recognition particle pro-
tein, is associated with adiponectin. Figure 2 shows
the SNP association patterns with phenotypes RQ and
TG at this QTL.The cis-SNP effects on gene expression
To test the function of the interrogated SNPs of the two
adiponectin QTLs, we evaluated the effect of each vari-
ant on the levels of transcripts produced from the genes
located within these two regions. We surveyed tran-
scripts that were robustly detectable after filtering
through our quality control procedures (see Methods).
We then assessed the association between QTL-specific
SNPs and each transcript annotated to the same locus.
Figure 3 shows the effects of SNPs of the chr5 locus
on expression of MYO10. We found strong signals clus-
tering in proximity to the transcription start site (TSS)
of MYO10. SNPs exhibiting the strongest cis-effects
(lowest p-value=5.43×10-6) are in high linkage disequi-
librium (data not shown) and span a 17 kb region that
has been shown previously to be highly important for
transcription initiation [31-34].
We further analyzed the relationship between MYO10
gene expression patterns in PWBC and key MetS pheno-
types for which we had found evidence of SNP-phenotype
associations (Table 2). Table 4 shows the levels of the cor-
relations between the level of MYO10 gene expression and
MetS traits. We found positive correlations of MYO10
expression with measures of adiposity. MYO10 expression
correlated negatively with plasma levels of adiponectin
(although this did not reach statistical significance) and
was positively correlated with plasma leptin at





Nearest gene Location Annotation
rs1955850 G 0.33 2.95 Weight NOVA1 intergenic post-transcription regulation
rs2332524 G 0.10 2.87 Height STXBP6 intergenic exocytosis
rs1955850 G 0.33 3.75 BMI NOVA1 intergenic post-transcription regulation
rs6574794 A 0.06 3.08 WC NOVA1 intergenic post-transcription regulation
rs1956993 C 0.09 2.92 HC AKAP6 intergenic signal transduction
rs17096124 G 0.03 3.81 WHR PRKD1 intron signal transduction
rs8007613 G 0.28 2.88 Fatkg NPAS3 intron Transcription regulation
rs41449149 T 0.07 3.45 Fatpct PRKD1 intergenic signal transduction
rs1111533 C 0.05 3.53 Leankg NPAS3 intron Transcription regulation
rs41449149 T 0.07 3.55 Leanpct PRKD1 intergenic signal transduction
rs10137682 G 0.37 3.35 SubQF NPAS3 intron Transcription regulation
rs12888531 C 0.06 3.59 VF SLC25A21 intron solute carrier
rs10137682 G 0.37 3.39 TAF NPAS3 intron Transcription regulation
rs11623278 G 0.46 4.16 RQ AKAP6 intergenic signal transduction
rs11161057 A 0.42 3.42 REE MIR548AI intergenic mircoRNA
rs10137682 G 0.37 3.50 REE/weight NPAS3 intron Transcription regulation
rs17414154 A 0.05 3.43 REE/Lean AKAP6 intron signal transduction
rs17112354 A 0.08 2.95 FG BC148262/MIR4307/
LOC100505967/NOVA1
intergenic cDNA clone/mircoRNA/non coding RNA/
paraneoplastic disease antigens
rs2105274 G 0.39 3.40 FI NOVA1 intergenic paraneoplastic disease antigens
rs1626390 C 0.11 3.48 IGR EGLN3 intergenic Transcription regulation
rs2105274 G 0.39 3.47 HOMA NOVA1 intergenic paraneoplastic disease antigens




rs17114954 A 0.04 3.32 SG MIR548AI downstream mircoRNA
rs8012040 G 0.46 3.53 AIR BC148262 /LOC100505967/
NOVA1
intergenic cDNA clone / non coding RNA/
paraneoplastic disease antigens
rs10483452 C 0.27 3.82 DI PPP2R3C intron signal transduction
rs8006023 A 0.05 4.60 TG NPAS3 intron transcription regulation
rs8004607 C 0.10 4.44 TC NPAS3 intron transcription regulation
rs712300 C 0.26 4.09 LDL-c EGLN3 intergenic transcription regulation
rs8004607 C 0.10 3.71 cal. LDL-c NPAS3 intron transcription factor
rs10136818 T 0.02 3.63 HDL-c STXBP6 intergenic exocytosis
rs12886242 G 0.12 2.61 HMED NPAS3 intron Transcription regulation
rs17103757 G 0.05 3.84 LMEDn BRMS1L intergenic transcription regulation
rs847501 C 0.35 3.29 LDLppd BRMS1L intergenic transcription regulation
rs10134570 C 0.02 3.83 BMED NPAS3 intron Transcription regulation
rs1951039 A 0.45 4.26 sBP STXBP6/NOVA1 intergenic exocytosis/paraneoplastic disease antigens
rs10498306 C 0.13 4.17 dBP MIR548AI/PRKD1 intergenic microRNA/signal transduction
rs8007613 G 0.28 3.04 Pulse NPAS3 intron Transcription regulation
rs9322942 A 0.33 3.43 Adiponectin SRP54 intron signal recognition particle 54kDal
rs17427680 C 0.05 3.12 Leptin G2E3 intergenic protein sorting
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Table 3 MetS SNP association with phenotypes and their gene annotation at 14q13 QTL (Continued)
rs1440983 A 0.04 3.64 TNF-alpha PRKD1 intergenic signal transduction
rs11849533 C 0.17 3.67 IL-1B NPAS3 intron Transcription regulation
rs17406989 T 0.09 2.87 IL-6 NPAS3 intron Transcription regulation
SNPs within 1 LOD reduction from the linkage peak were tested for associations against the 42 phenotypes. Annotated genes and their known function were
derived from the NCBI build 36 human genome assembly. Annotations were determined at the position and within 250kb up- and downstream of the associated
SNP. Data shown in column “-Log10(p)” are levels of the highest association. SNP associations that exceed statistical QTL-specific significance threshold
are bolded.
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Table 5 summarizes all the biologically relevant can-
cer or pro-inflammation genes, annotated by the SNP
associations and gene expression correlations with
MetS phenotypes under the adiponectin QTL peaks
of 5p14 and 14q13. Figures 1 and 2 show SNP/
phenotype association plots of SNPs located within
these QTLs that we consider to be of the highest
priority based on their biological relevance, in rela-
tion to the phenotypes from which the top candidate
gene was identified.Figure 1 Manhattan plots of SNP associations with MetS phenotype
association of identifier phenotypes with all SNPs in the region determin
(NCBI36/hg18)]. Vertical axis represents minus logarithm of the p-values a
QTL-wide significance thresholds are shown by the dash lines. Red lines
indicate suggestive level pα=0.1= 4.11×10
-5). A) Association patterns of all
by UCSC genome browser (31, 32) are shown below the Manhattan plo
located in gene CDH18 (framed in orange). B) SNP associations with BM
strongest associations are mapped to MYO10, shown framed in the lowe
(pointed by an arrow) is mapped to be 400kb upstream of CDH18, framDiscussion
As previously seen in other studies [36,37] plasma
adiponectin was significantly correlated with several of the
clinical outcome and biologic precursor phenotypes of
MetS in our cohort. It correlated with BMI, total body fat
mass, visceral vs. subcutaneous fat distribution, insulin to
glucose response indices, levels of plasma lipids/lipoprotein
density profiles, and circulating levels of leptin and cyto-
kines (Table 1). As expected, the key clinical traits of MetS
are also inter-correlated with each other in our subjects
(Additional file 1: Table S1). Using adiponectin levels within adiponectin QTL at 5p14. Dark blue dots depict levels of
ed from 1 LOD reduction from the peak [chr5: 9,792,000-23,021,100
nd horizontal represents the chromosomal position (Mb). Levels of
indicate the significant level (pα=0.05= 2.11×10
-5) and blue lines
the SNPs of the region with weight phenotype. Transcripts defined
t, by blue bars. SNPs that show highest association with weight are
I. C) SNP associations with plasma levels of adiponectin. SNPs with
r panel and the blown-up picture. The second locus of peak signals
ed in green.
Figure 2 Manhattan plots of SNP associations with MetS phenotypes within adiponectin QTL at 14q13. Dark Blue dots depict levels of association
of identifier phenotypes with all SNPs in the region determined from 1 LOD reduction from the peak [chr14: 23,131,000-36,761,868 (NCBI36/hg18)]. Vertical
axis represents minus logarithm of the p-values and horizontal represents the chromosomal position (Mb). Levels of QTL-wide significance thresholds are
shown by the dash lines. Red lines indicate the significant level (pα=0.05= pα=0.05=1.86×10
-5) and blue lines indicate suggestive level pα=0.1= 3.72×10
-5).
A) Association patterns of all the SNPs of the region with RQ phenotype. Transcripts defined by UCSC genome browser (31, 32) are shown below the
Manhattan plot, by blue bars. SNPs that show highest association with weight are located in gene AKAP6 (framed in red). B) SNP associations with
triglycerides. SNPs that show highest associations with triglycerides are mapped to the transcription factor gene NPAS3.
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adiponectin-linked QTLs (5p14 and 14q13) in our
study population. We now have used SNP association
and the cis-effects of local SNPs on PWBC expres-
sion to discover MetS-related genes within these twoFigure 3 Cis-effects of tagging SNPs located at chr5p14 on PWBC exp
by –log10p-value) with MYO10 gene expression of each tagging-SNP of the 1 LO
hg18) is plotted against its respective genomic position using LocusZoom [35].
plot. Red horizontal line shows the significance cutoff after Bonferoni-correction
plot shows the degree of correlation with rs2434960, the variant with the highe
is depicted on the right. Genes mapped to this region are shown below the plo
gene is framed in orange. In the blow-up figure on the right, functional genom
cis-effect evidence in our analysis is shown in the UCSC Genome Browser vie
are labeled as red dots on MYO10 gene track. ENCODE functional genomics tra
modifications (H3K4Me1, H3K4Me3 and H3K27Ac), DNase hypersensitivity clusteQTLs. By doing so, we were able to identify multiple
novel genes that have significant associations with individ-
ual MetS phenotypes. These genes can be mechanistically
grouped into four categories (Table 5): (1) cell-cell ad-
hesion and mobility (CDH18, CDH12, CTNND2 andression of MYO10 gene. Association significance level (shown
D-score drop of adiponectin QTL at chr5: 9,792,000-23,021,100bp (NCBI36/
The position of each typed SNPs is also depicted in black bars above the
(pα=0.05=1.4×10
-5). The color of the dot that represents each SNP on the
st significance levels of cis-effect on MYO10 expression. Correlation (r2) scale
t, with their directionality on the chromosome strand depicted. MYO10
ics data from ENCODE consortium [33,34] of the region with the strongest
w [31,32]. The four SNPs with the highest significance levels of cis-effects
cks shown include evidence of enhancer- and promoter-associated histone
rs and transcription factor binding assays.
Table 4 Correlation (standardized beta ± SE) of PWBC
expression levels of MYO10 transcript
MetS phenotype MYO10 (β±SE)
Body Composition Total Fat Mass (Fatkg), kg 0.04 ± 0.11
Total Fat Mass (Fatpct), % 0.20 ± 0.11*
Total Lean Mass (Leankg), kg −0.06 ± 0.10
Total Lean Mass (Leanpct), % −0.20 ± 0.11*
Adipokines Adiponectin, ng/mL −0.02 ± 0.09
Leptin, ng/mL 0.16 ± 0.09*
*Correlations with suggestive significance (p<0.1).
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PPP2R3C); (3) transcription (NPAS3, BRMS1, Nova-1,
EGLN3 and TAG); and (4) protein sorting (MARCH11
and FBXL7). It is interesting that many of these genes
are known to play a role in cancer biology. The link
between MetS and increased cancer risk is well
known [38] thus our prioritized genes provide a pos-
sible explanation for the observed association between
MetS and cancer.
Our strongest SNPs associations on the chr5 QTL
clustered around genes in the cell-cell adhesion path-
ways (Table 2 and Figure 1). Cell to cell adhesion is a
key event in major cellular processes including prolifera-
tion, mobility, differentiation and cell death. It is also a
basic mechanism facilitating the paracrine communica-
tion between cells. CDH18 is a cadherin that is
expressed in multiple tissues, most prominently in the
CNS [39] and is one of several cadherin genes located in
this region of chromosome 5. The CDH18 gene was
most strongly associated with weight, BMI, waist cir-
cumference and RQ in our cohort, indicating a possible
role in the development of body composition. Mechanis-
tically this could be mediated via a role in CNS but since
cell adhesion is a phenomenon that is integral to the re-
gional expansion of adipose tissue it is possible that the
gene may play a direct role in the preferential deposition
of fat into the visceral abdominal region, a fundamental
phenotype of MetS. Aberrations leading to alteration of
cell adhesion are linked with several tumor types. N-
cadherins specifically have been reported to play a role
in the formation, growth, invasion [40] and migration of
malignant tumors in various settings, including Crohn’s
disease [41] and prostate cancer [42,43]. Deletions in the
region of the chromosome 5 cadherin cluster have been
specifically associated with risk of some malignancies
[44]. Thus it is possible that the CDH18 gene and other
nearby genes identified in cohort (including CTNND2,
CDH12 and MYO10) play a mechanistic role in the ob-
served connection between MetS and cancer risk.
Our strongest SNP association signals for plasma
adiponectin levels clustered near the geneMYO10 on chr5.
MYO10 protein is a member of the myosin family and hasa role in trafficking adhesion molecules including integrins
and adherins [45]. It is essential for the initiation, stability
and formation of filopodia, a “finger-like” cellular protru-
sion that can sense environmental cues and a key structure
for cell motility including cancer cells [46]. In a recent
study of breast cancer with poor prognosis, expression of
MYO10 is significantly increased in patients with breast
cancer. The expression of MYO10 also differentially clus-
tered with clinocopathological markers including p53 mu-
tation, estrogen receptor (ER), tumor grade and patient
survival [46]. In our analysis, variants in MYO10 also asso-
ciated with lean body mass, LDL diameter and IL-6, thus
reflecting pleiotropy in its role in MetS, possibly via modu-
lation of adiponectin levels. No data has shown that
MYO10 directly transports CDH18, however our data sug-
gest that these two genes might work together in a bio-
logical pathway that predisposes individuals with MetS for
carcinogenesis or high risk of metastasis. Our evaluation of
the function of these tagging SNPs (or SNPs in LD with
these) suggested strong cis-effects of variants near the TSS
ofMYO10. This region thus may harbor causal SNP(s) that
directly affect binding of transcription factors. Results from
human cell lines recently published by the ENCODE pro-
ject has demonstrated that this 17 kb region is marked
with transcription-activating histone modifications, is
highly accessible to protein binding, and can be bound by
multiple transcription factors in chromatin immuno-
precipitation assays (Figure 3) [33,34]. Our approach
therefore is able to efficiently identify genetic elements
that can function in influencing genes important for
our traits of interest.
At the QTL on chr14, SNP associations clustered
near genes that function as signal transducers like
AKAP6 and transcription factors like NPAS3 (Table 3
and Figure 2). The protein encoded by AKAP6 is an an-
chor protein for the well-characterized protein kinase A
(PKA), also known as AMP-activated protein kinase
(AMPK). AKAPs compartmentalize AMPK, thereby
regulating AMPK’s biological functions. AKAPs by them-
selves may also function as integrators of AMPK-related
signal transduction pathways [47]. AMPK is a key regula-
tor sensing cellular energy status and systemic energy
balance [48] and mediates the effects of adipose tissue ki-
nins including adiponectin and leptin in regulating body
weight, glucose and lipid homeostasis [48]. It may also
play a role in cancer via several processes including ar-
resting of cell cycle progression, triggering inhibition of
protein synthesis, and cell growth required in cell prolif-
eration [49]. AMPK is also known to overcome growth
factor signaling from a variety of stimuli mediated by the
proto-oncogenes Akt and ERK. The AMPK signaling net-
work also contains a number of tumor suppressor genes
including p53, which is a universal tumor suppressor
[50]. AMPK is thus one of the most prominent biological
Table 5 Summary of prioritized genes associating MetS with cancer or inflammation
Biological mechanism Annotated
genes
Biological function Association identifier
phenotype
Relevance to cancer and/or inflammation Evidence
Cell cell adhesion and
cell motility
CDH18 A member of Calcium-dependent cell adhesion
molecules subfamily type 2 N-cadherin, affects
morphogenesis, growth and tissue homeostasis.
weight, BMI, WC, HC
and RQ
Formation, growth, invasion and migration of
malignant tumors, including Crohn’s disease and
prostate cancer. Ectopic expression in breast cancer
cells promotes motility, invasion and metastasis.
SNP associations
CDH12 A member of the cadherin family. leptin Its homologue, CDH11, promotes synovial fibroblasts
to secret pro-inflammatory cytokines.
SNP associations
CTNND2 A partner molecule in the cadherin complex. It is
a transcription activator.
BMED Involvement in cancer as above SNP associations
MYO10 An associate of the cadherin-catenin complex Leankg, LDLppd,
adiponectin, IL-6
Function unclear, presumably involved in cancer
as above
SNP associations, SNP cis-effects on
gene expression, expression/MetS
phenotype correlations
Signal transduction AKAP6 An anchor protein for the AMP-activated protein kinase,
a regulator of glycogen, sugar and lipid metabolism.
HC, RQ and REE/Lean It might be involved in any cancer biology that
is mediated through p53
SNP associations




It is involved in prostate cancer through E-cadherin
phosphorylation
SNP associations
PPP2R3C It encodes the regulatory component of the protein
ser/thr metallo-phosphatase. May regulate MCM3AP,
which is a phosphorylation-dependent DNA replication
initiation enzyme. Its homologue also play a role in the
activation-induced cell death of B-cells.
DI It may presumably be involved in cancer biology that
relates MCM3. These include brain and thyroid cancer.
It may also be involved in inflammation through its
hypothetical function in B cell apoptosis.
SNP associations
Transcription TAG A novel tumor antigen gene that is immunogenic. REE,FG, HOMA, HMED Testis cancer, skin melanoma and myelogenous
leukemia.
SNP associations
NPAS3 A transcription factor which regulates neurogenesis,
glucose metabolism and the linkage of the two.
Fatkg, Leankg, SubQF,
TAF, REE/weight, TG,
TC, cal. LDL-c, pulse,
IL-1β, IL-6
It is a brain tumor suppressor and a marker for
survival.
SNP associations,
SNP cis-effects on gene expression
NKX2-8 A homeobox transcription factor Weight and height Fetal liver and hepatocellular carcinoma and
lung cancer
SNP associations
BRMS1L A homologue to transcription factor BRMS1, which
functions in a histone acetylase complex that repress
target genes
LMEDn and LDLppd Breast cancer progression and melanoma metastasis SNP associations
NOVA1 It is a neuron-specific tumor antigen that has RNA-
binding activity and functions to ensure correct
pre-mRNA splicing of target RNA
BMI, WC, FG, FI, SI, AIR,
HMED and sBP
It is involved in the paraneoplastic motor disorder SNP associations
EGLN3 It is a hydroxylase for target transcription factor HIF
and mediates apoptosis in neuronal cells under
development
IGR and LDL-c It is involved in hemangioblastoma, clear cell renal
carcinoma and formation of pheochromocytoma
SNP associations
Protein sorting MARCH11 An ubiquitin ligase that is implicated in protein sorting
and transport from trans-Golgi network to
multivascular body.
Fatkg, FI, SI and IL-1β Might be involved in pro-inflammatory
cardiomyopathy.
SNP associations
FBXL7 Another ubiquitin ligase specific for phosphorylated
protein degradation.
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MetS to cancer [50].
NPAS3, associated with several lipid and cytokine phe-
notypes in our cohort, encodes a neuronal basic helix-
loop-helix (Per, Arnt, Sim) domain transcription factor,
belonging to a family that has been reported to be cru-
cial for neuronal development and maintenance [51] and
exerts a regulatory role in neurogenesis and brain glu-
cose metabolism [52]. Brain tissue of an NPAS3 knock-
out mouse model shows altered levels of the glycolysis
metabolites, the pentose phosphate shunt and Krebs
cycle components, and aberrant behavior in mice. Glu-
cose sensing by the brain is known to have effects on
feeding, behavior, weight, weight control and associated
metabolic consequences, as in MetS. NPAS3 can also
modulate cell cycle proliferation, apoptosis, migration
and cell invasion and exhibits features of a tumor sup-
pressor. Absence of NPAS3 expression in astrocytomas
is a negative prognostic marker for survival [53].
Increasing evidence has suggested that peripheral
blood can be used to reveal the relative differences in
gene expression among individuals [54,55]. Obtaining
gene expression information using peripheral blood is
simple and minimally invasive, making it possible to
assay a large number of our subjects. Furthermore, obes-
ity can be considered as a low-grade inflammation state
[56], due to long-term low-level immune response trig-
gered by accumulation of macrophages in visceral adi-
pose tissue, chronic insulin resistance, adiponkine and
cytokine production and malfunctional cardiovascular
performance [57,58]. Profiling gene expression in per-
ipheral blood therefore may capture changes in the ex-
pression of genes important for components of MetS
such as visceral adiposity. In our analysis, we found
some significant signals of SNP associations near pro-
inflammatory genes. MARCH11 (associated with fat, FI,
SI and IL-1beta in our cohort) and FBXL7 (associated
with WHR in our cohort) belong to the family of ubiqui-
tin ligases that are engaged in the process of protein
sorting and transport of deformed ones from the trans-
Golgi network [59,60]. MARCH11 expression was shown
in the Gene Expression Omnibus (GEO) database to be
higher in patients with inflammatory dilated cardiomy-
opathy. FBXL7, an F-box protein family member, is spe-
cific for sorting of phosphorylated proteins and their
degradation. Thus MARCH11 and FBXL7 may be in-
volved in inflammation, a characteristic phenotype of
MetS.
We do acknowledge that PWBC can reveal only a por-
tion of the total gene expression information and that
profiling it in other focal tissues like adipose and liver
might reveal complementary genomic information. Fur-
ther exploration of the expression levels of the other
genes associated with MetS (and known to play a role incancer biology) in other target tissues might help to re-
veal their gene expression correlations with MetS traits.
Our study has identified several novel as well as previ-
ously reported genes whose SNP variants are associated
with phenotypes that are important components of
MetS. e.g. genome-wide study of the genetic basis of in-
sulin resistance reported that a variant of AKAP6 was as-
sociated with BMI-adjusted fasting insulin (5×10-7) in a
meta-analysis cohort of European descent [61]. NPAS3
was found in the current study to be associated with a
multitude of phenotypes including two inflammatory
markers IL-1β and IL-6. Interestingly, in a recent report
of a genome-wide search for associations between SNPs
and biomarkers of systemic inflammation before and
after an anti-inflammatory drug treatment, a variant of
NPAS3 was found to be one of the two most signifi-
cantly associated gene loci with levels of C-reactive pro-
tein [62], and studies of visceral adiposity and BMI
identified FBXL7, MARCH6 and PRKD1 as candidate
loci [63-65].
Conclusions
In the present study of a family cohort of Northern
European origin, we conducted a comprehensive ana-
lysis using both SNP associations and gene expression
correlations on two previously identified adiponectin
QTLs and identified 14 novel genes associated with
various metabolic syndrome traits. We found that many
of these genes are involved in fundamental cellular
functions that could provide a mechanistic link between
the development of metabolic syndrome and cancer
biology as well as systemic inflammation. Further stud-
ies are needed to elucidate the roles these genes play in
the development of metabolic syndrome and its rela-
tionship with cancer biology. Eventually this could lead
to the design of novel diagnostic markers and/or
pharmaceutical agents for the prevention and treatment
of MetS patients who are at higher risks for developing
cancer and systemic inflammation.
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